European Archives - Page 4 of 1282 - European Medical Journal

chemotherapy

ASAP Trial Finds No Benefit for Pre-Transplant Chemotherapy in AML

The ASAP trial shows immediate transplantation matches chemotherapy outcomes in AML, with genetics driving survival differences.

HCV Incidence Falls as Scotland Nears WHO Target

HCV incidence among people who inject drugs in Scotland has halved since 2015, bringing WHO elimination targets within reach.

Low Pillow Height Linked to Throat Reflux in Patients With GORD

A new study finds that sleeping with a low pillow height significantly increases the risk of throat reflux in patients with GERD, suggesting that simple lifestyle changes like elevating the head during sleep may ease symptoms.

Stevens-Johnson Syndrome Therapy: Breakthrough Study

Recent research highlights programmed cell death mechanisms, apoptosis and necroptosis, as central to Stevens-Johnson syndrome and toxic epidermal necrolysis pathology.

Innovative, Automated Breathing Operator Developed for Preterm Infants

A new automated device, BOBBY, provides gentle tactile stimulation to help preterm infants breathe independently and reduce nurse intervention delays.

Enzalutamide Plus Leuprolide Boosts Survival Outcomes

After eight years, overall survival reached 78.9% in the combination group, compared with 69.5% among those receiving leuprolide alone.

Glucocorticoids Reduce Mortality in Community-Acquired Pneumonia

Adjunctive low-dose glucocorticoids lower 30-day mortality in adults with community-acquired pneumonia in low-resource hospital settings.

Listening to and Playing Music for Dementia Prevention

New research links music for dementia prevention to lower cognitive decline risk and better long-term brain health.

blood stem cell

Study Uncovers Key Role of P-Selectin in Ageing Blood Stem Cells

Researchers identify P-selectin as key driver of blood stem cell ageing and inflammation-linked decline.

Peanut Sublingual Immunotherapy Shows Long-Term Benefits

A recent study examined 36 months of peanut sublingual immunotherapy in children aged 1–4 years, assessing both desensitisation and remission outcomes.